MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly … – GlobeNewswire (press release)
GlobeNewswire (press release) |
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly …
GlobeNewswire (press release) BUFFALO, N.Y., May 21, 2018 (GLOBE NEWSWIRE) — MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced positive interim results from a multicenter Phase II … |
